Daily megavoltage computed tomography in lung cancer radiotherapy: correlation between volumetric changes and local outcome.

PURPOSE To assess the predictive or comparative value of volumetric changes, measured on daily megavoltage computed tomography during radiotherapy for lung cancer. PATIENTS AND METHODS We included 80 patients with locally advanced non-small-cell lung cancer treated with image-guided intensity-modulated radiotherapy. The radiotherapy was combined with concurrent chemotherapy, combined with induction chemotherapy, or given as primary treatment. Patients entered two parallel studies with moderately hypofractionated radiotherapy. Tumor volume contouring was done on the daily acquired images. A regression coefficient was derived from the volumetric changes on megavoltage computed tomography, and its predictive value was validated. Logarithmic or polynomial fits were applied to the intratreatment changes to compare the different treatment schedules radiobiologically. RESULTS Regardless of the treatment type, a high regression coefficient during radiotherapy predicted for a significantly prolonged cause-specific local progression free-survival (p = 0.05). Significant differences were found in the response during radiotherapy. The significant difference in volumetric treatment response between radiotherapy with concurrent chemotherapy and radiotherapy plus induction chemotherapy translated to a superior long-term local progression-free survival for concurrent chemotherapy (p = 0.03). An enhancement ratio of 1.3 was measured for the used platinum/taxane doublet in comparison with radiotherapy alone. CONCLUSION Contouring on daily megavoltage computed tomography images during radiotherapy enabled us to predict the efficacy of a given treatment. The significant differences in volumetric response between treatment strategies makes it a possible tool for future schedule comparison.

[1]  Walter J Curran,et al.  Combined chemoradiotherapy regimens of paclitaxel and carboplatin for locally advanced non-small-cell lung cancer: a randomized phase II locally advanced multi-modality protocol. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  N. Hanna Simultaneous Chemoradiotherapy Compared With Radiotherapy Alone After Induction Chemotherapy in Inoperable Stage IIIA or IIIB Non–Small-Cell Lung Cancer: Study CTRT99/97 by the Bronchial Carcinoma Therapy Group , 2008 .

[3]  K. Tournel,et al.  Toxicity and outcome results of a class solution with moderately hypofractionated radiotherapy in inoperable Stage III non-small cell lung cancer using helical tomotherapy. , 2010, International journal of radiation oncology, biology, physics.

[4]  R Mackie,et al.  A new approach to dose escalation in non-small-cell lung cancer. , 2001, International journal of radiation oncology, biology, physics.

[5]  D. Verellen,et al.  Volumetric response analysis during chemoradiation as predictive tool for optimizing treatment strategy in locally advanced unresectable NSCLC. , 2009, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[6]  N. O'Rourke,et al.  Concurrent chemoradiotherapy in non-small cell lung cancer. , 2010, The Cochrane database of systematic reviews.

[7]  R. Jeraj,et al.  Automatic registration of megavoltage to kilovoltage CT images in helical tomotherapy: an evaluation of the setup verification process for the special case of a rigid head phantom. , 2006, Medical physics.

[8]  Dirk Verellen,et al.  Innovations in image-guided radiotherapy , 2008, Nature Reviews Cancer.

[9]  J. Herndon,et al.  Radiosensitization with carboplatin for patients with unresectable stage III non-small-cell lung cancer: a phase III trial of the Cancer and Leukemia Group B and the Eastern Cooperative Oncology Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  D. Verellen,et al.  Innovations in image-guided radiotherapy , 2007, Nature Reviews Cancer.

[11]  H. Choy,et al.  The novel taxane analogs, BMS-184476 and BMS-188797, potentiate the effects of radiation therapy in vitro and in vivo against human lung cancer cells. , 2001, International journal of radiation oncology, biology, physics.

[12]  O. Brodin,et al.  Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials , 1995 .

[13]  M. Ridder,et al.  Toxicity report of a phase 1/2 dose‐escalation study in patients with inoperable, locally advanced nonsmall cell lung cancer with helical tomotherapy and concurrent chemotherapy , 2009, Cancer.

[14]  Patrick A Kupelian,et al.  Initial experience with megavoltage (MV) CT guidance for daily prostate alignments. , 2005, International journal of radiation oncology, biology, physics.

[15]  H. Choy,et al.  Enhancement of radiation effects by combined docetaxel and carboplatin treatment in vitro. , 1999, Radiation oncology investigations.

[16]  J. Debus,et al.  Docetaxel-based induction therapy prior to radiotherapy with or without docetaxel for non-small-cell lung cancer , 2006, British Journal of Cancer.

[17]  L. Peters,et al.  Relationship of mitotic arrest and apoptosis to antitumor effect of paclitaxel. , 1996, Journal of the National Cancer Institute.

[18]  G. Storme,et al.  9101 Toxicity report of a phase I/II dose escalation study in inoperable locally advanced non-small cell lung cancer with helical tomotherapy and concurrent chemotherapy , 2009 .

[19]  J. Van Dyk,et al.  Optimization of megavoltage CT scan registration settings for thoracic cases on helical tomotherapy , 2007, Physics in medicine and biology.

[20]  O. Nascimben,et al.  Radiotherapy versus radiotherapy enhanced by cisplatin in stage III non-small cell lung cancer. , 1992, International journal of radiation oncology, biology, physics.

[21]  H. Groen,et al.  Concomitant radio-chemotherapy based on platin compounds in patients with locally advanced non-small cell lung cancer (NSCLC): a meta-analysis of individual data from 1764 patients. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[22]  W. Curran,et al.  Effect of overall treatment time on outcomes after concurrent chemoradiation for locally advanced non-small-cell lung carcinoma: analysis of the Radiation Therapy Oncology Group (RTOG) experience. , 2005, International journal of radiation oncology, biology, physics.

[23]  H. Bartelink,et al.  Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer. , 1992, The New England journal of medicine.